Rising BioSciences, Inc.
RBII
Other OTC0.00
USD
- -
- -
ISIN
US76761W1080
CUSIP
76761W108
Return %
Stock
S&P500
1Y
-90.00
26.53
3Y
900.00
76.60
5Y
-98.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Arthur Hall
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 30 North Gould Street Sheridan AR United States of America
- IPO Date
- Apr 28, 2017
- Website
- risingbiosciences.org
- Similar Companies
- Business
- Rising BioSciences, Inc. (RBII) is a research and development company focused on oral and topical cannabis and non-cannabis based pharmaceuticals, including medical marijuana products; it develops and manufactures pharmaceutical products such as bactericide disinfectants like Oxy Thyme, which holds EPA Establishment Number 96322-OH-3 and Organic Materials Review Institute listing; clinical strength stem cell creams like RSB0238 and RBS0346; and operates business units encompassing a physician's practice management company for cannabis treatments targeting chronic pain, opioid addiction, and terminal patients, alongside behavioral health medical treatments for substance addiction across Midwest branches. Founded in 1998 and headquartered in Sandusky, Ohio, with a listed address at 30 North Gould Street, Suite 6113, Sheridan, Wyoming, the company conducts operations in the United States within the pharmaceuticals and biotechnology sector, trading on OTCPK with a focus on alternative patient care treatments. Recent developments include resumption of trading in September 2020 following a suspension, announcement of a new 10,000 square foot headquarters and bottling plant in Sandusky, Ohio, certified by the EPA, and progression of products like RBS0346 clinical strength stem cell cream into production, reflecting ongoing advancements in its pharmaceutical compounding under FDA standards despite prior SEC trading halt in August 2020 over accuracy concerns.